Evidence map›Paper›PMID 42761842›Full record

ArticleIJID regions2026

Posterior reversible encephalopathy syndrome associated with

Hamidreza Naderi, Alireza Sedaghat, AbouSaleh Sobhi, Mohammadreza Seyedzadeh, Hamidreza Mirzaei, Parsa Aryanpour, Saber Esmaeili

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hamidreza NaderiDepartment of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Alireza SedaghatFaculty of Critical Care Medicine, Lung Disease Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
AbouSaleh SobhiFaculty of Critical Care Medicine, Lung Disease Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammadreza SeyedzadehDepartment of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamidreza MirzaeiDepartment of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Parsa AryanpourDepartment of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Saber EsmaeiliWHO Collaborating Centre for Vector-Borne Diseases, Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Posterior reversible encephalopathy syndrome (PRES) is an uncommon but serious neurological complication characterized by headache, seizures, visual disturbances, and altered mental status, and associated with parieto-occipital vasogenic edema on neuroimaging. Rickettsial infections have rarely been reported as triggers of PRES. Methods: In this report, we describe the case of a 26-year-old man with rickettsial infection in Iran who developed a diffuse petechial rash, acute kidney injury, recurrent seizures, and bilateral cortical blindness. Results: Brain magnetic resonance imaging revealed extensive parieto-occipital hyperintensities consistent with PRES. An indirect immunofluorescence assay demonstrated a fourfold rise in immunoglobulin M titers against Conclusion: This case highlights

Indexed as

CiprofloxacinIranMediterranean spotted feverPosterior reversible encephalopathy syndromeRickettsia conorii

Identifiers

PMID42761842
PMCPMC13587721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.